Follicular lymphoma (FL) is the most common indolent nonHodgkin lymphoma (1,2) and generally has a long natural history with multiple remissions and relapses (3). Randomized control trials (RCTs) of multiple chemotherapy regimens have resulted in varying event-free survival (EFS) but have not indicated a survival advantage attributed to one regimen compared with another (4-6). The addition of interferon alpha to chemotherapy improves overall survival (OS) but is associated with substantial toxicity and is not generally accepted as standard therapy (7). Several RCTs of patients with FL have demonstrated the benefit of adding rituximab to primary therapy (8) with regard to OS and to maintenance therapy (9) with regard to progression-free survival.
Follicular lymphoma (FL) is the most common indolent nonHodgkin lymphoma (1, 2) and generally has a long natural history with multiple remissions and relapses (3) . Randomized control trials (RCTs) of multiple chemotherapy regimens have resulted in varying event-free survival (EFS) but have not indicated a survival advantage attributed to one regimen compared with another (4) (5) (6) . The addition of interferon alpha to chemotherapy improves overall survival (OS) but is associated with substantial toxicity and is not generally accepted as standard therapy (7) . Several RCTs of patients with FL have demonstrated the benefit of adding rituximab to primary therapy (8) with regard to OS and to maintenance therapy (9) with regard to progression-free survival.
Several RCTs have explored the possibility that intensification of chemotherapy beyond hematological limiting toxicity with autologous stem cell rescue (10-13) may improve EFS. With the recent RCTs of chemoimmunotherapy showing an OS benefit (8, 14) , the impact of any toxic therapy on OS should be questioned. Although narrative reviews are available (3, (15) (16) (17) , to our knowledge, no systematic review and meta-analysis has addressed this issue. Herein, we report the results of a systematic review and meta-analysis of the available RCTs examining the impact of highdose chemotherapy with autologous stem cell transplantation (ASCT) vs any chemotherapy in the primary management of adults with advanced FL on OS, EFS, treatment-related mortality (TRM), 
Background
The impact of high-dose therapy and autologous stem cell transplantation (ASCT) vs conventional-dose chemotherapy in the initial management of adults with advanced follicular lymphoma (FL) on overall survival remains uncertain. We performed a systematic review of the randomized clinical trials addressing this question.
Methods
We searched MEDLINE, EMBASE, CENTRAL, American Society of Hematology, American Society of Clinical Oncology, BIOSIS, PAPERSFIRST, PROCEEDINGS, clinical trials registries, and bibliographies of relevant studies for randomized clinical trials comparing myeloablative chemotherapy with ASCT to any chemotherapy in adults with untreated advanced FL. We performed a meta-analysis using random effects models to estimate overall survival, event-free survival, and risks of adverse outcomes. Statistical heterogeneity was calculated by using the I 2 statistic.
Results
Seven trials proved eligible, four of which provided data from 941 patients that could be included in a metaanalysis and three of which remain unpublished. In two of the trials, patients in both arms received rituximab during the induction treatment. Moderate quality evidence from the three trials that reported overall survival (n = 701 patients) suggests that ASCT did not result in improved overall survival (hazard ratio of death = 0.99, 95% confidence interval [CI] = 0.73 to 1.33) . Low-quality evidence from the four trials of 941 patients suggests improvement in event-free survival in favor of ASCT (hazard ratio of death = 0.54, 95% CI = 0.36 to 0.82) with substantial heterogeneity (I 2 = 80%). Adverse outcomes of treatment-related mortality, myelodysplastic syndrome, acute myeloid leukemia, and solid tumors were not different between the two arms (relative risk [RR] of treatment-related mortality = 1.04, 95% CI = 0.29 to 3.70; RR of myelodysplastic syndrome/acute myeloid leukemia = 2.19, 95% CI = 0.45 to 10.55; I 2 = 48%; and RR of solid tumors = 1.30, 95% CI = 0.33 to 5.08). The absolute risk of death from treatment was 14 per 1000 patients for those who received chemotherapy and 15 per 1000 for those who received ASCT (range = 4-52).
Study Selection
We included all RCTs of previously untreated FL adult patients that compared high-dose myeloablative chemotherapy with autologous peripheral blood or bone marrow stem cell transplantation, whether published or unpublished, in any language, which enrolled patients of any histological grade (World Health Organization grades I, II, and III) and clinical risk factors. Acceptable treatment regimens included any form of chemotherapy with or without radiation or immunotherapy during or after chemotherapy. Only trials with available data, either published or retrieved through personal communication, were included in the meta-analysis. Two reviewers (M. Al Khabori, J. R. de Almeida) independently screened all citations. Additional information (gathered from the full text and by contacting the authors) was retrieved for citations that were deemed potentially eligible. Disagreement was resolved by discussion.
Data Abstraction
Two reviewers (M. Al Khabori, J. R. de Almeida) abstracted the data independently using a common data collection form that had been piloted specifically for this review. Any disagreement on the data extracted from the studies was resolved by discussion and review of the full text or the original source. Corresponding authors of all eligible trials were contacted for missing and updated data on OS, EFS, TRM, MDS/AML, secondary malignancies, and questions regarding methodological issues and to confirm results and resolve questions on methodology of the trials. We received further data by personal communication for three trials from Dr C. Sebban (OS, EFS, TRM, method of sequence generation, allocation concealment, and number of patients who were lost to follow-up), Dr M. Ladetto (OS, EFS, TRM, MDS/AML, and secondary malignancies), and Dr Deconinck (OS, EFS, TRM, MDS/AML, solid tumor incidence, method of sequence generation, allocation concealment, and number of patients who were lost to follow-up).
Risk of Bias Assessment
The two reviewers independently abstracted information from six design elements related to risk of bias, including sequence generation, concealment of allocation, blinding, completeness of follow-up, selective reporting and other biases using categories of low, unclear, and high risk (18) . We calculated the Cohen kappa coefficient (k) to assess the agreement between the two reviewers
CONTEXT AND CAVEATS

Prior knowledge
Different chemotherapies have been combined with autologous stem cell transplantation (ASCT) in randomized clinical trials for follicular lymphoma, a type of non-Hodgkin lymphoma. The effect of these combinations on event-free survival varies, and a comparison of the survival benefits elicited by these different immunechemotherapies has not been reported.
Study design
A systematic review and meta-analysis of randomized control trials comparing chemotherapy alone with chemotherapy and ASCT for follicular lymphoma were performed. Overall survival, event-free survival, and other adverse patient outcomes were compared for patients who received chemotherapy alone vs chemotherapy with ASCT. The quality of evidence for each analysis was also assessed.
Contribution
Seven randomized clinical trials met the predetermined eligibility criteria. Moderate quality evidence of three trials that reported overall survival indicated that high-dose chemotherapy with ASCT did not improve the overall survival of adult follicular lymphoma patients. On the basis of low-quality evidence from four trials, event-free survival was longer for patients who received chemotherapy with ASCT. Other adverse outcomes and the absolute risk of death from treatment did not differ between the two treatment arms.
Implications
Long-term follow-up of patients in trials is needed to better assess the effect of ASCT on event-free survival. Future clinical trials measuring the effect of combining ASCT with high-dose chemotherapy on overall survival are needed.
Limitations
Because of low-quality evidence, the suggested improvement in event-free survival for patients treated with chemotherapy, and ASCT should be investigated in additional trials with longer follow-up. Some data from unpublished trials were unavailable for analysis and may have led to potential publication bias.
From the Editors
Downloaded from https://academic.oup.com/jnci/article-abstract/104/1/18/2567739 by guest on 24 January 2019 when categorizing the six elements and reported it as overall agreement. Any disagreement on the quality rating between the two reviewers was resolved by discussion and consensus. The lack of blinding was not considered to result in a high risk of bias, given the objective nature of the outcomes used in this systematic review (OS, EFS, TRM, MDS/AML, and secondary malignancies).
Outcome Measures
OS and EFS were defined according to the International Workshop criteria (19) . OS was defined for all patients from the date of entry into the trial to the time of death from any cause. For patients with complete and partial response to chemotherapy, EFS was defined as the date of entry into the trial until death from any cause or progression of disease. We also reported definitions by authors not using the International Workshop criteria (19) . TRM was defined as deaths related to chemotherapy or ASCT within 1 year of completion of treatment. Secondary malignancies were defined as any MDS, AML, or solid tumors that developed after chemotherapy or ASCT.
Analysis and Data Synthesis
For binary outcomes, the treatment effect was expressed as relative risk (RR) with its 95% confidence interval (CI). For the time to event outcomes, the treatment effect is expressed as hazard ratio (HR) with its 95% confidence interval. If the hazard ratio is not reported in the article and no information could be collected from the primary authors, we used Parmar methods (20, 21) to estimate the hazard ratio from the available data. Cohen kappa coefficient (22) was calculated to measure the agreement between the two reviewers (M. Al Khabori, J. R. de Almeida) on the relevant studies identified at the screening and full text stages. All meta-analyses used random effect models. Heterogeneity was assessed by Cochrane x 2 analysis and by measuring I 2 (23) . We explored the following a priori hypothe ses to explain heterogeneity: baseline risk [high risk defined as ≥3factors on the FLIPLI or IPS (24, 25) ]; use of rituximab; follow-up (≤5 vs >5 years); and type of analysis (intention-to-treat and per protocol). For the baseline risk, the subgroup analysis of interest was not reported in the published trials; therefore, we were only able to conduct the subgroup comparison between trials. Trials with high-risk patients compromising more than a third of the study population were considered as high risk. For the OS and EFS outcomes, we expected the benefit of ASCT to be greater in high-risk patients and in per protocol analyses and lower with use of rituximab and longer follow-up. For the TRM, MDS/AML, and secondary malignancy outcomes, we expected higher event rates with longer follow-up. Other analyses and x 2 tests of subgroup interaction were performed using RevMan 5 (Review Manager 5 computer program, version 5.0. Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2008) according to methods described by Deeks et al. (26) . The GRADE criteria (27) were used to summarize the evidence gathered in the systematic review for each outcome in the following domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias. The results were presented in an evidence profile. All statistical tests were two-sided and carried out at a = .05. The P value for comparing heterogeneity between subgroups was calculated using Cochrane x 2 (23).
Results
Search Results
The search strategy identified 1661 citations ( Figure 1 
Characteristics of the Included Studies
Seven RCTs were identified (Table 1 ) and included in the systematic review, but only four RCTs with data from 941 patients were included in this meta-analysis (11-13,31) ( Table 2) , as outcome data were not available for pooling from three of the trials. All trials were multicenter (information was not available for Portlock, NCI-V89-0192), two-arm, parallel prospective RCTs. The sample sizes ranged from 67 (30) to 469 (29) adult participants with previously untreated FL. In the four trials with available data, the median age was approximately 50 years. High-risk patients constituted less than a third of the patients enrolled except in one trial (11) in which they represented 58% of the population. A variety of induction, mobilization, and high-dose therapy regimens were used in the transplant and chemotherapy arms of the four trials, as detailed in Table 1 . In two of the trials, patients in both arms received rituximab during the induction treatment (11, 30) . The median follow-up duration was up to 5 years for two trials (11, 12) and approximately 9 years for the other two trials (13, 31) . OS was reported by three trials (11, 13, 31) . The trial described by Lenz et al. (12) did not report OS, and the author did not provide the data. EFS was reported for three trials (11, 13, 31) with definitions consistent with that of the International Workshop criteria (19) . In the study reported by Lenz et al. (12) , only progression-free survival was reported as the disease control outcome. Two (28, 29) of three RCTs with no available data were found on the National Cancer Institute website (www.cancer.gov): Portlock (NCI-V89-0192) and the European Organization for Research and Treatment of Cancer (NCT00003152). These studies started in 1990 and 1997, respectively, and both terminated enrollment. Available details of the design and interventions are presented in Table 1 . The study by Portlock (NCI-V89-0192) planned to include 106 patients with non-Hodgkin lymphoma (stage 3 or 4) in complete remission following ProMACE-MOPP chemotherapy (cyclophosphamide, doxorubicin, etoposide, mustargen, oncovirin, procarbazine, and prednisone). The NCT00003152 study planned to include 469 patients with advanced FL (stage 3 or 4) in partial or complete remission after eight 3-weekly courses of CVP chemotherapy (cyclophosphamide, vincristine, and prednisone). Both studies have not been published, and further information could not be retrieved from the corresponding investigators. The results of the third trial, reported by Meckenstock et al. (30) , were reported at an interim analysis in a conference abstract. The available data on the patients and interventions are detailed in Table 1 , although no further information could be retrieved from the corresponding author. Participants were adults aged less than 60 years with advanced FL. With a median follow-up of 23 months, both the EFS and OS were similar between the two arms (64 evaluable patients of 67 total enrolled).
Risk of Bias
Two reviewers (M. Al Khabori, J. R. de Almeida) independently assessed the reports with a very good overall agreement (k = 0.72). The lowest agreement was in the other bias category in which either reviewer felt that limited reporting of quality domains might have biased the results. Of four trials with available data (11) (12) (13) 31) , one trial reported their sequence generation (11) and two others provided sequence generation by personal communication (13, 31) ; all were computer generated and consistent with low risk of bias. Allocation concealment (central randomization) was reported by the four trials (11) (12) (13) 31) . Patients and physicians were not blinded in any of the trials and it was not stated (not available through personal communication), if blinding was used at the time of data collection, analysis, or article preparation. Only the trial reported by Ladetto et al. (11) specifically stated the loss to follow-up and methods used to deal with the loss to follow-up. All trials performed the analysis as intention to treat except for one trial (12) in which analysis was reported as per protocol, although P was stated for the intention-to-treat analysis. One trial (11) was stopped early because benefit in EFS favoring ASCT was observed.
Outcomes
The three studies that reported OS (11,13,31) enrolled 701 patients and reported no statistically significant difference in OS (a pooled HR of OS = 0.99, 95% CI = 0.73 to 1.33, P heterogeneity = .65; I 2 = 0%, 95% CI for I 2 = 0% to 90%) ( Table 3 and Figure 2 ). The Consolidative extended field radiotherapy will be administered.
EORTC NCT00003152 (29)
Multicenter two arms parallel prospective controlled 469 (planned) High-dose chemotherapy with cyclophosphamide and total body irradiation followed by autologous stem cell transplantation will be performed.
IFN-a will be delivered subcutaneously three times per week for a maximum of 3 y.
Meckenstock et al.
(30)
Two arms parallel prospective controlled 67 (64 evaluable) Three courses of conventional CHOP followed by two courses of HAM preceding high-dose therapy with BEAM, and autologous peripheral blood stem cell transplantation. Rituximab was added to every cycle after the first cycle. # For this study, bulky disease was defined as tumors greater than 7 cm in diameter. ** For this study, bulky disease was defined as tumors greater than 5 cm in diameter. * ASCT= autologous stem cell transplantation; CI = confidence interval; CR = complete response; EFS = event-free survival; HR = hazard ratio; MDS/AML = secondary myelodysplasia/acute myeloid leukemia; PP = per protocol; RCT = randomized controlled trial; RR = relative risk. † The pooled survival probability for the chemotherapy arm across all studies is not available given the lack of individual patient data. quality of evidence was rated moderate because of imprecision (Table 3) . Also, an estimation of the absolute event rates (derived from observed events in the study) for patients who received chemotherapy only and ASCT were unavailable (Table 3) . All four trials, with a total of 941 patients, suggested an improvement in EFS in favor of ASCT (11-13,31) (pooled HR of EFS = 0.54, 95% CI = 0.36 to 0.82; P heterogeneity = .002; I 2 = 80%, 95% CI for I 2 = 48% to 93%) ( Figure 3 ). This heterogeneity was because of the duration of follow-up and a statistically significant subgroup effect (P < .001). The median follow-up was 4-5 years for two trials (11,32) (pooled HR of the two trials = 0.38, 95% CI = 0.28 to 0.52, I 2 = 0%) and 9 years for the other two (13,31) (pooled HR for the two trials = 0.77, 95% CI = 0.61 to 0.97, I 2 = 14%) (Figure 3 ). Comparing the trial using rituximab as part of the initial therapy vs those that did not, the EFS was statistically significantly decreased (HR of trials with rituximab = 0.38, 95% CI = 0.25 to 0.59 vs pooled HR of trials not employing rituximab = 0.60, 95% CI = 0.38 to 0.95; I 2 = 79%; P for subgroup effect = .02). The quality of evidence (27) was rated low because of inconsistency, early termination, and potential publication bias (Table 3) .
Three studies reported TRM (11, 13, 31) with five treatmentrelated deaths among 346 patients who underwent ASCT and five deaths among 355 patients who received chemotherapy. The difference in TRM between the two arms was not statistically significant (pooled RR = 1.04, 95% CI = 0.29 to 3.70, P heterogeneity = .51; I 2 = 0%, 95% CI for I 2 = 0% to 90%). The absolute risk across the chemotherapy arms was 14 deaths per 1000 patients, whereas the calculated absolute risk with ASCT on the basis of the above relative risk is 15 in 1000 (range = 4-52 deaths per 1000 patients). The quality of evidence (27) was rated low because of imprecision, early termination of one RCT, and potential publication bias (Table 3) .
Data regarding the development of MDS/AML were reported for three trials (11) (12) (13) 31) . In the transplant arm, 13 of 346 patients developed MDS/AML during follow-up compared with six of 355 patients in the chemotherapy arm. The difference in MDS/ AML rates between the two arms was not statistically significant (pooled RR = 2.19, 95% CI = 0.45 to 10.55, P heterogeneity = .14; I 2 = 48%, 95% CI for I 2 = 0% to 85%) ( Figure 4 ). The absolute risk across the chemotherapy arms was 17 in 1000, whereas the calculated absolute risk with ASCT strategy on the basis of the above Figure 2 . Forest plot of overall survival. I 2 was calculated according to the method described by Deeks et al. (23) . The first author, year of publication, and reference are given for each study. The hazard ratios (boxes) with 95% confidence intervals (CIs, horizontal lines) were calculated, and the pooled hazard ratio (diamond) was estimated with generic inverse variance (IV) using random effect analysis. The weight of each study's contribution to the overall effect calculated from random effect analyses is given and is also reflected by the size of the box. All statistical tests were two-sided. The P value for comparing heterogeneity between subgroups was calculated using Cochrane x 2 (23) . ASCT = autologous stem cell transplantation; chemo = chemotherapy. Figure 3 . Forest plot of event-free survival comparing studies with longvs short-term follow-up (FU). I 2 was calculated according to the method described by Deeks et al. (23) . The first author, year of publication, and reference are given for each study. The hazard ratios (box) with 95% confidence intervals (CIs, horizontal lines) were calculated for each study, and the pooled hazard ratio (diamond) was estimated with generic inverse variance (IV) using random effect analysis. The weight of each study's contribution to the overall effect calculated by random effect analyses is given and reflected by the size of each box. All statistical tests were two-sided. The P value for comparing heterogeneity between subgroups was calculated using Cochrane x 2 (23) . ASCT = autologous stem cell transplantation; chemo = chemotherapy.
relative risk is 37 deaths in 1000 patients (range = 8-170 in 1000). Most of the heterogeneity was created by the study reported by Sebban et al. (13) . Baseline risk, use of rituximab, or follow-up duration did not explain this heterogeneity (for all analyses, P subgroup effect = .32). The quality of evidence (27) was rated as low because of inconsistency, imprecision, and early termination of one RCT (Table 3) .
Three trials (11, 13, 31) reported data on solid tumors. There were 16 and 12 solid tumors, respectively, observed in a sample of 346 ASCT patients and 355 standard-dose therapy patients. The solid tumor rates for the two treatment arms were similar (pooled RR for second solid tumors = 1.30, 95% CI = 0.33 to 5.08, P heterogeneity = .20; I 2 = 38%, 95% CI for I 2 = 0% to 81%). The absolute risk across the chemotherapy arms was 34 in 1000 patients, whereas the calculated absolute risk with ASCT strategy on the basis of the above relative risk is 44 in 1000 (range = 11-173 in 1000). The quality of evidence (27) was rated low because of imprecision and early termination of one RCT (Table 3) .
Discussion
In this systematic review and meta-analysis, we found moderate quality evidence that high-dose chemotherapy and ASCT did not improve OS in adults with previously untreated FL. EFS was superior for the transplant arm compared with the chemotherapy arm, albeit with substantial heterogeneity. This survival benefit comes at the expense of MDS/AML at a relative risk that cannot exclude a large increase risk in the transplant arm. The TRM and rates of secondary solid tumors were similar between those who received chemotherapy only vs ASCT.
The estimate of the hazard ratio for OS was rated moderate on evidence quality because of imprecision. Although OS comparisons were not reported in all of the trials, we do not anticipate publication bias as this would likely bias the pooled estimate toward a positive treatment effect. Use of chemoimmunotherapy including rituximab in subsequent treatment for the nontransplanted patients may have contributed to the lack of survival difference (9) . The higher rate of MDS/AML in the transplant arm in trials with longer follow-up may contribute to the lack of a difference in survival that was observed.
The EFS was rated low on evidence quality on the basis of the inconsistency, per protocol analysis used by one of the studies contributing to the pooled estimate (12) , and the likelihood of publication bias. Three trials (28) (29) (30) found through the systematic search had no published data and were not included in the metaanalysis. One of the three excluded trials showed lack of benefit of the transplantation strategy in an interim analysis (30) . This publication bias may have biased the results toward benefit and, if included, could change the pooled estimate toward no difference or even harm. In our review, we pooled the hazard ratios of progression-free survival reported by Lenz et al. (12) with hazard ratios of EFS from the other trails. Pooling hazard ratios of progression-free survival with hazard ratios of EFS would likely increase the apparent statistical significance of the difference in EFS and for our study, bias the pooled hazard ratio in favor of the ASCT assuming similar induction failures in both treatment arms.
Although the heterogeneity in the EFS was substantial, it could be explained by the duration of follow-up. This subgroup analysis suggests that on long-term follow-up, the treatment effect disappears. Although this subgroup analysis was between trials, it was planned a priori, and likely represents a true subgroup effect (33) . Furthermore, it is consistent with the natural history of this indolent lymphoma (16) and the tendency for patients to experience multiple relapses. No curative treatments are available, except for a highly selected group receiving allogeneic stem cell transplantation (34) .
The serious methodological limitations (early termination and per protocol analysis) along with the imprecision and the likelihood of publication bias resulted in a low evidence quality rating for TRM. The MDS/AML outcome was also rated low for the inconsistency and the limitation of early termination of one trial. None of the a priori hypotheses to explore heterogeneity explained this inconsistency. The pooled estimate with the 95% confidence interval suggests large potential harm that may be introduced by ASCT, although it also includes the small potential harm of chemotherapy.
Because the introduction of monoclonal antibody therapy for indolent lymphoma is relatively recent, only two trials (11, 30) used rituximab as part of their treatment in all patients in both treatment arms. The relevance of any conclusions regarding the The first author, year of publication, and reference are given for each study. The number of new patients with myelodysplastic syndrome/ acute myeloid leukemia and the total number of patients evaluable in the study, respectively, in the ASCT arm are given. The number of new patients diagnosed with myelodysplastic syndrome/acute myeloid leukemia and the total number of patients evaluable in the study in the chemotherapy arm are also shown. The relative risk (boxes) with corresponding 95% confidence intervals (CIs, horizontal lines) for each study was calculated, and the pooled relative risk (diamond) was estimated with generic inverse variance (IV) by random effect analysis. Also, the weight of the contribution to the overall effect of each study was calculated from random effect analyses and is also reflected by the size of each box. All statistical tests were two-sided. The P value for comparing heterogeneity between subgroups was calculated using Cochrane x 2 (23). ASCT = autologous stem cell transplantation; chemo = chemotherapy.
effectiveness of therapy intensification with ASCT in light of the evolution of the standard of care for FL remains limited given the survival benefit shown with adding rituximab to chemotherapy (35) . For example, the median time to progression was 32 months after rituximab-containing chemotherapy vs 15 months for chemotherapy alone (P < .001) in a landmark clinical trial (35) . In addition, maintenance rituximab improves the median progression-free survival compared with observation (51.5 months for rituximab vs 14.9 months for observation, P < .001), as shown in relapse-refractory settings (14) . The subgroup effect of trials using rituximab in our analysis suggests that use of rituximab has a synergistic effect when combined with high-dose chemotherapy and ASCT. The interpretation of this finding is limited by the publication bias of at least one other trial (30) that used rituximab and found a non-statistically significant difference.
There are a number of limitations associated with our systematic review and meta-analysis. The lack of complete data from unpublished trials may have led to a potential publication bias. Trials with no statistically significant treatment effect or those that stopped early because of toxic effects in the ASCT arm are more likely not to be published. This tendency would bias EFS toward an apparent benefit. No formal test of publication bias was done because of the small number of studies analyzed. The other limitation was the power, especially in the OS outcome. With a pooled sample size of 701 patients, we have 80% power to detect a minimum treatment effect (HR = 0.65) using a two-sided alpha of 0.05 (36) . Therefore, one cannot rule out a smaller effect size than that of a hazard ratio of 0.65. Finally, the subgroup analyses were done comparing treatment effects between trials and not within trials as those subgroup analyses were not reported for each trial.
The current systematic review and meta-analysis showed no benefit for high-dose chemotherapy and ASCT in OS for patients with previously untreated FL. Long-term follow-up is needed from clinical trials to better estimate the impact of ASCT on EFS and the risk of secondary MDS/AML. In addition, data from the unpublished trials should be made available for a more complete assessment of the treatment effect, and to guide the development of future clinical trials. Trials of ASCT in the context of current chemoimmunotherapy approaches in FL are needed to further evaluate the ability of intensification of therapy using ASCT to improve OS.
